2013 News Releases

Keyword Search
 
2017 | 2016 | 2015 | 2014 | 2013 | 2012
DateTitle 
06/03/13NeuroDerm Awarded $1M by The Michael J. Fox Foundation for the Clinical Development of ND0612 for Parkinson’s Disease
Ness Ziona, Israel, June 3, 2013 /– NeuroDerm, Ltd. was informed today that it was awarded, for the second time, a grant of $1M by The Michael J. Fox Foundation for Parkinson’s Research (MJFF) to support the clinical development of its subcutaneously delivered drug for the treatment of Parkinson’s disease. These funds, part of the Foundation’s 2013 Therapeutic Pipeline program, will support an upcoming phase 2 clinical trial with ND0612, a novel drug for the treatment of Parkinson’s disease. ND0... 
Printer Friendly Version
03/04/13NeuroDerm Announces Positive Results of a Phase I Study of ND0612L for the Treatment of Parkinson’s Disease
Ness Ziona, March 4th, 2013 / — NeuroDerm, Ltd. announced today the results of a Phase I safety and pharmacokinetic trial of ND0612, a novel drug formulation for the treatment of Parkinson’s disease. ND0612L is a proprietary levodopa/carbidopa liquid formula administered continuously sub-cutaneously through a patch pump. It is designed to provide steady levodopa blood levels for the reduction of motor complications in Parkinson’s disease. Results of this study support the continued development o... 
Printer Friendly Version